Loss of Sexually Dimorphic Liver Gene Expression upon Hepatocyte-Specific Deletion of Stat5a-Stat5b Locus

Minita G. Holloway, Yongzhi Cui, Ekaterina V. Laz, Atsushi Hosui, Lothar Hennighausen, and David J. Waxman

Hepatocyte-specific, albumin-Cre recombinase-mediated deletion of the entire mouse Stat5a-Stat5b locus was carried out to evaluate the role of signal transducer and activator of transcription 5a and 5b (STAT5ab) in the sex-dependent transcriptional actions of GH in the liver. The resultant hepatocyte STAT5ab-deficient mice were fertile, and unlike global STAT5b-deficient male mice, postnatal body weight gain was normal, despite a 50% decrease in serum IGF-I. Whole-liver STAT5ab RNA decreased by approximately 65–85%, and residual STAT5 immunostaining was observed in a minority of the hepatocytes, indicating incomplete excision by Cre-recombinase. Quantitative PCR analysis of 20 sexually dimorphic, liver-expressed genes revealed significant down-regulation of 10 of 11 male-specific genes in livers of male hepatocyte STAT5ab-deficient mice. Class I female-specific liver genes were markedly up-regulated (de-repressed), whereas the expression of class II female genes, belonging to the Cyp3a subfamily, was unaffected by the loss of hepatocyte STAT5ab. STAT5ab is thus required in the liver for positive regulation of male-specific genes and for negative regulation of a subset of female-specific genes. Continuous GH infusion strongly induced (>500-fold) the class II female gene Cyp3a16 in both wild-type and hepatocyte STAT5ab-deficient male mice, indicating sex-specific transcriptional regulation by GH that is STAT5ab independent. In contrast, hepatocyte STAT5ab deficiency abolished the strong suppression of the male-specific Cyp2d9 by continuous GH seen in control mouse liver. Analysis of global STAT5ab-deficient mice indicated no essential requirement of STAT5a for expression of these sex-specific liver Cyp genes. Thus, the major loss of liver sexual dimorphism in hepatocyte STAT5ab-deficient mice can primarily be attributed to the loss of STAT5b. (Endocrinology 148: 1977–1986, 2007)
The widespread effects that global STAT5b deficiency has on sex-dependent liver gene expression can be explained by two distinct mechanisms. First, the loss of STAT5b in the liver may directly impair GH signaling in hepatocytes leading to the observed loss of sex-dependent gene expression. Alternatively, GH-activated STAT5b may contribute to the feedback inhibition of somatostatin neurons in the hypothalamus (17), such that the loss of hypothalamic STAT5b impairs the negative feedback inhibition of pituitary GH release and perturbs the plasma GH profile in a manner that feminizes liver gene expression and body growth rates. Indeed, plasma GH levels may be elevated in global STAT5b-deficient mice (13). In hypophysectomized mice, GH pulse replacement restores male-characteristic body growth and male liver gene expression in the case of wild-type but not global STAT5b-deficient mice, evidencing the intrinsic GH pulse resistance of mice with a global deficiency in STAT5b (18). Nevertheless, these studies do not establish whether the loss of liver STAT5b per se is a major cause of the observed feminization of liver and body growth phenotypes.

Presently we characterize mice with a hepatocyte-specific deletion of the entire Stat5a-Statb locus (Stat5ab) to assess the requirement of hepatic STAT5ab for the liver gene expression and body growth phenotypes previously associated with global STAT5b deficiency. Hepatocyte-specific STAT5b deficiency was introduced using the Cre-Lox system to delete the entire Stat5b gene in hepatocytes, in an effort to avoid any potential complications of hypomorphic alleles associated with residual STAT5 protein fragments present in some Stat5b-disrupted mouse models (14, 19). The deletion was extended to include the adjacent Stat5a gene, which codes for a protein more than 90% identical with STAT5b that exhibits many similar but also some unique properties (20, 21). Using this mouse model, we compared the effects of STAT5ab loss in hepatocytes with that of global STAT5b deficiency. Our findings lead us to conclude that hepatocyte STAT5b is not required for normal postnatal growth but plays an essential role in the establishment and/or maintenance of sexually dimorphic gene expression in the liver. These findings are discussed in terms of the mechanisms through which hepatocyte STAT5b regulates liver sexual dimorphism.

### Materials and Methods

**Knockout mice**

Hepatocyte-specific STAT5ab-deficient mice were generated by mating C57BL/6 × 129J mice having a floxed Stat5a-Stat5b locus (22) with albumin promoter-regulated Cre transgenic mice (FVB/N) (23). Cre is a bacteriophage P1-derived recombinase that cuts atloxP-tagged genes. Livers from 8- to 12-wk-old hepatocyte STAT5ab-deficient males and females, and floxed controls, were excised, snap frozen in liquid nitrogen, and stored at −80°C until use. Livers were excised from 8- to 9-wk global Stat5b gene-disrupted mice and corresponding wild-type controls (13). Stat5a gene-deleted livers (24, 25) were from 7- to 9-wk-old mice, except for two control males and two STAT5a-deficient males, which were from 6-wk-old mice. Hepatocyte-specific STAT5ab-deficient male mice, and male floxed controls, were given a continuous infusion of rat GH at 20 ng/g body weight per hour for 7 or 14 d using Alzet osmotic minipumps using methods described previously (15). Serum IGF-I was measured by direct RIA (catalog no. 22-IGF-R21; ALPICO Diagnostics, Windham, NH) carried out by Oksana Gavrilova of the National Institute of Diabetes and Digestive and Kidney Diseases metabolism core [National Institutes of Health (NIH), Bethesda, MD]. Serum GH levels were measured by RIA carried out by Dr. A. F. Parlow (National Hormone and Pituitary Program, University of California, Los Angeles, Medical Center, Torrance, CA).

**Primer design and qPCR analysis**

qPCR primers specific to each gene were designed using Primer Express software (Applied Biosystems, Foster City, CA) and are shown in Table 1 or as reported earlier (15, 26). qPCR primers selected for Mup1/2/6/8 were unable to distinguish between Mup genes 1, 2, 6, and 8 because the percent nucleotide identities of these genes ranged up to 97%. Similarly, the Gspt1 and Gspt2 RNAs (~98% identity) (27). Expression profiles obtained using the Mup and Gspt primers therefore reflect a composite expression pattern based on the most abundant RNAs in each liver sample. For convenience, the Mup and Gspt genes are referred to as single genes in the text. Methods for liver RNA isolation, cDNA synthesis, and real-time qPCR using SYBR Green I chemistry to quantify relative levels of each RNA were described previously (15). Amplification of a single, specific product during qPCR cycling was verified by examination of dissociation curves of each amplicon. Data are graphed after normalizing to the 18S rRNA content of each sample. Statistical analysis was carried as indicated in each figure using GraphPad Prism software version 4 (GraphPad, San Diego, CA). P < 0.05 was considered significant. Each of the 20 sex-specific liver-expressed genes examined showed a very similar pattern of sex-dependent expression in all three mouse strains used in this study, minimizing the impact of any background strain differences between the mouse models.

**TABLE 1. Mouse qPCR primer sets and GenBank accession numbers**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Oligo numbers</th>
<th>GenBank</th>
<th>Amplicon (nucleotides)</th>
<th>Forward primer (5’–3’)</th>
<th>Reverse primer (5’–3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyp3a16*</td>
<td>1738/1739</td>
<td>NM_007820</td>
<td>851–949</td>
<td>AGACGCCGCTTGGACTTATT</td>
<td>GGGCTGGTGAATCGGATTCCAG</td>
</tr>
<tr>
<td>Cyp39a1</td>
<td>1410/1411</td>
<td>NM_018887</td>
<td>918–968</td>
<td>TTTCTGGGCTGTCTTCCAGG</td>
<td>CTGTGTTTCCGCTTCACCAC</td>
</tr>
<tr>
<td>Elovl3</td>
<td>1650/1651</td>
<td>NM_007703</td>
<td>1421–1471</td>
<td>GGAGCAAGGCAACACAAACAA</td>
<td>GGCCTCAACGGCTTAGAAT</td>
</tr>
<tr>
<td>Hsd3b5</td>
<td>1623/1633</td>
<td>NM_008295</td>
<td>1380–1432</td>
<td>AGTCTCTAAGGCTTCGCCAAAT</td>
<td>CACAGCAGCAGTACCACAGC</td>
</tr>
<tr>
<td>Moxl1</td>
<td>1646/1647</td>
<td>NM_021509</td>
<td>1120–1170</td>
<td>GGTTGACCTTTTCCACACA</td>
<td>CGAATGAGAATCGGACATC</td>
</tr>
<tr>
<td>Nntt</td>
<td>1642/1643</td>
<td>NM_010924</td>
<td>549–599</td>
<td>GAGGGACCTCTGGAAGAGCAG</td>
<td>AGTAGACCGTTTGTTGACCC</td>
</tr>
<tr>
<td>Sloe1a1</td>
<td>1582/1629</td>
<td>NM_015979</td>
<td>2400–2451</td>
<td>TTCTACATTTACGAGCATTTCCT</td>
<td>ACCAAACATCCCTTCATGAGTTA</td>
</tr>
<tr>
<td>Stat5a</td>
<td>1640/1641</td>
<td>NM_023135</td>
<td>174–227</td>
<td>TGAGACAGCCGTTGCCAAAA</td>
<td>GCTTGGCAAGAAAGATTTCAA</td>
</tr>
</tbody>
</table>

qPCR primer pairs specific to each gene were designed as described in Materials and Methods. The position of the resultant PCR amplicon is indicated by nucleotide numbering based on the indicated GenBank accession numbers. Primer sequences and GenBank accession numbers for other genes characterized in this study are listed elsewhere (15, 26).

* Primers shown here were used for Fig. 6. Other data in this study were obtained using primers detailed elsewhere (26).
Antibodies

Rabbit polyclonal anti-STAT5b (sc-835) and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; sc-25778) antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Mouse monoclonal anti-β-catenin antibody was obtained from BD Transduction Laboratories (BD Biosciences, San Jose, CA).

Western blotting

Whole liver extracts (15 μg) were electrophoresed through standard 7.5% Laemmli sodium dodecyl sulfate polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were blocked for 1 h at 25 °C in 5% dry milk in 10 mM Tris HCl (pH 7.5), 0.1% Tween 20, and 0.1 mM NaCl followed by incubation at 25 °C for 1 hour with anti-STAT5b antibody (1:3000 dilution) or anti-GAPDH antibody (1:400 dilution). Washing of the blots, probing with secondary antibody, and detection using enhanced chemiluminescence (ECL kit, Amersham Pharmacia Biotech, Piscataway, NJ) used standard methods.

Immunostaining

Male STAT5ab-deficient and floxed (control) mice were injected with 2 μg GH/g body weight and killed 15 min later. Livers were excised, fixed in 4% paraformaldehyde overnight at 4 °C, embedded in paraffin, and sectioned at 5 μm. Sections were cleared in xylene and rehydrated. Digital Decloaking Chamber (Biocare Medical, Walnut Creek, CA) was used for antigen retrieval. After blocking for 30 min in PBS containing 0.1% Tween 20 and 3% goat serum, sections were incubated with antibodies against STAT5b (1:100). β-Catenin antibody (1:200) was used for counterstaining. The primary antibodies were allowed to bind overnight at 4 °C in the presence of blocking buffer. Fluorescent ligand-conjugated secondary antibodies (1:400, Alexa Fluor 488 and 594; Molecular Probes, Eugene, OR) were applied to sections for 30–60 min in the dark at room temperature and mounted with VectaShield containing DAPI (Vector Laboratories, Burlingame, CA). Sections were viewed under an epifluorescence-equipped BX51 microscope (Olympus, Tokyo, Japan). Images were captured with a Q Imaging Retiga Exi digital camera (Image Systems, Inc., Columbia, MD) and Image-Pro Plus 5.1 software. The percentage of STAT5-positive cells was estimated from the ratio of red stained to DAPI-stained nuclei based on three Flox control livers and two STAT5ab-deficient livers.

Results

Hepatocyte STAT5ab-deficient mice

Mice deficient in STAT5b expression in the liver were generated by mating mice with a floxed Stat5a-Stat5b locus (22) with albumin-Cre transgenic mice (23). The latter mouse model expresses the Cre recombinase under the control of the albumin promoter and can be used to effect hepatocyte-specific deletion in postnatal mice. Analysis of STAT5a and STAT5b expression by qPCR and Western blotting showed that the extent of knock out ranged from 65 to 85% at the RNA level (Fig. 1, A and B), with a somewhat greater decrease seen at the protein level (Fig. 1C). Immunofluorescence analysis of liver sections was performed on mice killed 15 min after GH pulse treatment, which concentrates STAT5ab in the nucleus. Strong nuclear STAT5ab staining was observed in more than 90% of the hepatocytes from GH-treated floxed (control) mice, whereas only up to approximately 20% of hepatocytes from the GH-treated hepatocyte STAT5ab-deficient mice displayed nuclear STAT5ab staining, which was generally weaker than in the control mice (Fig. 1D). The residual STAT5ab staining seen in individual hepatocytes indicates incomplete excision of the floxed STAT5ab-locus by the albumin-Cre-recombinase. In contrast, no residual STAT5a and STAT5b protein was detected in livers of mice with a global deficiency in STAT5a and STAT5b, respectively (13, 25) (also see Fig. 1C, lanes 2 and 3).

The hepatocyte STAT5ab-deficient mice were viable and fertile. In contrast to global STAT5b-deficient mice (13), no significant difference in growth rate was noted between floxed (control) male mice and hepatocyte STAT5ab-deficient male mice (e.g. body weight 20.2 ± 3.5 and 20.7 ± 3.0 g, respectively, at 6 wk; 26.9 ± 4.2 and 21.7 ± 3.2 g, respectively, at 9 wk; and 27.0 ± 2.4 and 28.7 ± 3.4 g, respectively, at 17 wk). Serum IGF-I levels were decreased by 50% at 8 wk in liver STAT5ab-deficient males, compared with controls (160 ± 53 and 325 ± 56 ng/ml, respectively; n = 4–5, P < 0.005), somewhat greater than the 30% decrease seen in global STAT5b-deficient mice (13) but less extensive than the 75% serum IGF-I decrease described in liver IGF-I-deficient mice (28). Analysis of serum GH indicated an increase in pituitary GH secretion, reflecting a decrease in feedback inhibition by IGF-I (28). Thus, four of 15 hepatocyte STAT5ab-deficient males had serum GH levels less than 10 ng/ml at the time the animals were killed, whereas eight of 14 floxed control mice had GH levels less than 10 ng/ml; serum GH levels were greater than 100 ng/ml in six of 15 hepatocyte STAT5ab-deficient and none of 14 floxed control males (P = 0.01, Student t test).

Dependence of male-specific genes on hepatocyte STAT5ab

Class I male-specific genes are down-regulated in global STAT5b-deficient male but not female livers (15). qPCR analysis of five class I male genes revealed significant decreases in expression in livers of hepatocyte STAT5ab-deficient male mice, with little or no effect seen in the corresponding females (Fig. 2). These results are similar to those seen in global STAT5b-deficient mice (15, 16), although the down-regulation of three of the genes (Gstr1, Slp, and Moxd1) was more complete in the global STAT5b-deficient male mice, most likely reflecting the incomplete loss of STAT5ab in the hepatocyte-specific STAT5ab mouse livers. Thus, hepatocyte STAT5ab is required for the high level, male-specific expression of all five genes.

Class II male genes differ from class I male genes insofar as they are down-regulated in both male and female liver with partial retention of male specificity in global STAT5b-deficient mice (15). qPCR analysis of six class II male genes revealed that the loss of hepatocyte STAT5ab significantly decreased expression of five of the genes (Fig. 3, A–D and F). These decreases were observed in both males and females for four of the genes (Fig. 3, A–D). For three of the five genes (Mup3, Hsd3b5, and Mup1/2/6/8), the decreases were somewhat less dramatic than those seen in global STAT5b-deficient mice (15, 16). The sixth class II male gene, Cyp2d9, did not show any significant or consistent decrease in expression in hepatocyte STAT5ab-deficient liver, in either males or females (Fig. 3E). Indeed, Cyp2d9 RNA levels were increased in female liver in the absence of STAT5ab. Thus, STAT5ab expression in hepatocytes is required for high level, male-specific expression of a majority of the class II male genes investigated.
Impact of hepatocyte-specific loss of STAT5ab on female-specific gene expression

Whole-body loss of STAT5b results in strong up-regulation of class I female genes in male liver, indicating that these genes are repressed in male mice, either directly or indirectly, by a mechanism that requires STAT5b (15). Presently we assayed the effect of hepatocyte STAT5ab deletion on six class I female genes, three of which were previously characterized by qPCR in the global STAT5b-deficient mouse model (Cyp2b9, Cyp2b13, Cyp2a4), and three of which were shown by microarray and qPCR analysis to have the same pattern of dependence on STAT5b (Cyp39a1, Nnmt, and Sult1el) (Ref. 16 and data not shown). All six genes exhibited the expected female specificity, which reached greater than 1000-fold in the case of Cyp2b13 in this mouse strain. Moreover, the loss of STAT5ab in male hepatocytes led to increased expression (de-repression) of all six genes, albeit to different extents (Fig. 4), indicating a requirement for hepatocyte STAT5ab for negative regulation of these genes in males.

Next, we characterized the impact of hepatocyte STAT5ab deficiency on the expression of three class II (i.e. STAT5b-independent) female genes, Cyp3a16, Cyp3a41, and Cyp3a44. The loss of STAT5ab in hepatocytes had no effect on the expression of these genes (Fig. 5), as was previously observed in global STAT5b-deficient mice (15).

Responsiveness of hepatocyte STAT5ab-deficient mice to continuous GH infusion

The above studies indicate that hepatocyte STAT5ab plays a minor role in sex-specific gene expression in female liver. We therefore investigated whether hepatocyte STAT5ab is required for the feminizing effect of continuous GH infusion, which mimics the GH profile of females. This feminization
is readily evident in wild-type male mice implanted with osmotic minipumps that release GH in a continuous manner for 7–14 d, which overrides the endogenous male plasma GH pulses and down-regulates male-specific liver genes and markedly inducing the expression of female-specific genes (15). The feminizing effect of continuous GH was evaluated in hepatocyte STAT5ab-deficient male mice by analyzing the impact of global Stat5a disruption on sexually dimorphic liver gene expression. Class I and class II male liver genes showed no substantial changes in their expression, in either males or females deficient in STAT5a (Table 2). STAT5a is thus dispensable in liver, and other tissues, for male-specific liver gene expression. Similarly, global loss of STAT5a had no significant effect on the expression of either class I or class II female genes (Table 2), supporting the conclusion that hepatic STAT5b, rather than hepatic STAT5a, is essential for the sex-specificity of liver gene expression.

**Impact of Stat5a gene disruption on sexually dimorphic liver gene expression**

The general consistency of the sex-specific liver gene expression profiles between hepatocyte STAT5ab-deficient mice (above) and global STAT5b-deficient mice (15) supports the hypothesis that STAT5b, rather than STAT5a, is the key required factor for liver sexual dimorphism. This hypothesis was tested by analyzing the impact of global Stat5a disruption on sexually dimorphic liver gene expression. Class I and class II male liver genes showed no substantial changes in their expression, in either males or females deficient in STAT5a (Table 2). STAT5a is thus dispensable in liver, and other tissues, for male-specific liver gene expression. Similarly, global loss of STAT5a had no significant effect on the expression of either class I or class II female genes (Table 2), supporting the conclusion that hepatic STAT5b, rather than hepatic STAT5a, is essential for the sex-specificity of liver gene expression.

**Discussion**

STAT5b is proposed to be a key mediator of the sex-dependent actions of GH in male liver. Global disruption of Stat5b is associated with GH pulse insensitivity, loss of male-characteristic body growth rates (13, 18), and feminization of male liver gene expression, as evidenced by the down-regulation of approximately 90% of male-predominant liver genes and the up-regulation (de-repression) of approximately 61% of female-dominant genes (16). It is unclear, however, whether this dramatic feminization of the male
liver reflects the loss of liver STAT5b per se, or alternatively, whether it is an indirect response to the loss of STAT5b in other tissues, e.g. the hypothalamus, which may disrupt the feedback inhibition of pituitary GH secretion and effectively feminize plasma GH profiles, thereby feminizing liver gene expression. Similarly, the reduced pubertal growth rate that is seen in global STAT5b-deficient male mice (13, 14) could result from either impaired liver STAT5b signaling, e.g. impacting production of the growth promoting factor IGF-I (13, 29), which is a direct target of STAT5b (30, 31), or a perturbation of pituitary GH secretory profiles secondary to the global loss of STAT5b.

These questions were investigated in the present study, in which the entire 110-kb Stat5a-Stat5b locus was specifically deleted in hepatocytes using Cre recombinase under the control of the albumin promoter. Quantification of whole liver STAT5a and STAT5b RNA revealed a 65–85% decrease in expression compared with floxed controls. This decrease is substantially less than the 98% or greater decreases observed in the case of liver-specific genes, such as albumin (23) and Hnf4 (26) using the same albumin-Cre knockout strategy. This difference could reflect the presence of STAT5ab in non-parenchymal cells in the liver (32), in which albumin is not expressed (33), or it could be the result of incomplete Cre excision of the Stat5ab locus in hepatocytes. Immunofluorescence analysis using GH-treated male mice revealed the presence of residual STAT5ab protein in up to approximately 20% of the hepatocytes (Fig. 1D), supporting the latter hypothesis. These findings are consistent with the incomplete excision of the Stat5ab locus, perhaps due to the large size (110 kb) of the floxed gene sequences.

In contrast to the whole-body growth retardation phenotype seen in global Stat5b-deleted mice (13, 14) and STAT5b mutated humans (34, 35), mice with hepatocyte-specific STAT5ab-deficiency showed no major changes in body growth rate, compared with floxed controls, despite a 50% decrease in circulating IGF-I. These observations establish that hepatocyte STAT5ab makes an important contribution to circulating IGF-I and furthermore demonstrate that hepatocyte STAT5ab is not essential for postnatal growth, which apparently requires the presence of STAT5ab in one or more extrahepatic tissues, such as bone and skeletal muscle (36). As a note of caution, albumin-Cre-mediated gene deletion is not manifest until after birth and in the case of hepatocyte STAT5ab is still not 100% complete at puberty and in early adulthood, leaving open the possibility that the residual hepatocyte STAT5ab fulfills an essential role in growth. The apparent hepatocyte STAT5ab independence of
postnatal growth reported here is, however, consistent with the lack of a growth phenotype in mice with a liver-specific deletion of the IGF-I gene (23) and contrasts with the striking requirement of hepatocyte STAT5ab for liver sexual dimorphism discussed below. These two sex-dependent phenotypes are also distinguished by their dependencies on the frequency of exogenous GH pulse administration in a hypophysectomized rat model (37).

Ten of the 11 male-specific genes presently examined were substantially down-regulated in livers of male hepatocyte STAT5ab-deficient mice. Whereas we cannot rule out the possibility that the elevated plasma GH levels seen in some individual hepatocyte STAT5ab-deficient males might contribute to the down-regulation of these genes or to the observed up-regulation of class I female genes, two findings suggest that the GH profiles in these mice are not feminized, making this possibility less likely. First, body growth rates were not feminized, and second, certain female-specific genes, e.g. Cyp3a16, were not induced to female-like levels in the hepatocyte STAT5ab-deficient male mice until the plasma GH profiles were feminized by continuous infusion of exogenous GH. Nevertheless, it is still possible that the plasma GH profile requirements for suppression of male genes or induction of class I female genes, differ from the requirements that govern body growth rates and the induction of class II female genes. Indeed, the distinct plasma GH concentration requirements for regulation of individual rat liver CYP genes (38) are consistent with the latter possibility.

One of the male-specific genes that is down-regulated in global STAT5b-deficient male liver, Cyp2d9 (15), was not significantly suppressed in hepatocyte STAT5ab-deficient livers. Thus, this gene did not show the strong dependence on hepatocyte STAT5ab that was seen with other male-specific genes. Nevertheless, STAT5ab was required for the suppression of Cyp2d9 by continuous GH, a finding that may help explain the up-regulation of this gene in females with hepatocyte-specific STAT5ab deficiency. The difference between mouse models in the response of Cyp2d9 to the loss of STAT5b is not likely to reflect feminization by the circulating GH profiles in the global STAT5b-deficient male mice, given the intrinsic unresponsiveness of Cyp2d9 to suppression by continuous GH presently seen in hepatocyte STAT5ab-deficient livers.

Class I female genes were strongly up-regulated in male but not female mouse liver in the absence of hepatocyte STAT5ab, demonstrating that hepatocyte STAT5ab plays an essential role in the silencing of these genes that occurs in wild-type male liver. STAT5ab could effect this negative

FIG. 4. De-repression of class I female genes in STAT5ab-deficient (KO) male livers. qPCR analysis of liver RNA samples, data presentation and statistical analysis were as described in Fig. 2, with mean control male levels set to 1. All six class I female genes were up-regulated to varying extents upon loss of STAT5ab in male mouse liver. In the case of Cyp39a1, Cyp2a4, and Cyp2b13, up-regulation was seen in five, six, and eight of the eight hepatocyte-specific STAT5ab-deficient male livers examined, respectively. Mean RNA levels were significantly different from floxed male controls for these three genes as judged by t test but did not reach significance by the more stringent ANOVA with Bonferroni post hoc test. Data for Cyp2b13 in STAT5ab-deficient males are based on n = 7 liver samples; the eighth liver displayed an RNA level 8-fold higher than the average of the seven other male samples.

Holloway et al. • Liver Sexual Dimorphism in STAT5a-STAT5b KO Mice


1983

Downloaded from endo.endojournals.org by David Waxman on April 19, 2007
regulation by a direct mechanism, e.g. by binding to putative negative regulatory elements associated with these female-specific genes. Alternatively, the inhibitory effect of STAT5ab could be indirect, e.g. mediated by epigenetic mechanisms or by male-specific transcriptional repressors whose expression is induced by STAT5ab (6), consistent with the delayed induction of class I female genes seen in livers of male mice infused with GH continuously (15). The increased secretion of GH secondary to the loss of hepatocyte STAT5ab, presently seen in individual hepatocyte STAT5ab-deficient male mice, could also contribute to the up-regulation of class I female genes, as noted above. However, class II female genes, belonging to the Cyp3a gene family, did not respond to the loss of STAT5b in either model of STAT5b deficiency, indicating that their expression is STAT5ab independent. Our finding that continuous GH treatment induces Cyp3a16, even in males with hepatocyte STAT5ab deficiency, strengthens this conclusion. In contrast, continuous GH treatment down-regulated the male-specific Cyp2d9 in control male mice but not in hepatocyte STAT5ab-deficient male mice, highlighting the requirement of STAT5ab for some, but not all, of the sex-specific hepatic effects of continuous plasma GH stimulation.

Comparison of the effects of hepatic STAT5ab deficiency to the response to global deletion of either Stat5a or Stat5b indicated that the major effects of hepatocyte STAT5ab de-
ficiency described here can largely be ascribed to the loss of STAT5b. Thus, ablation of STAT3a, whose coding sequence is greater than 90%, identical with that of STAT5b and whose protein and mRNA abundance is 90–95% lower than that of STAT5b (25), had little effect on the sex-dependent liver genes examined. This finding does not, of course, rule out a role for STAT5a in the regulation of other sex-specific hepatic genes. Previously we had observed a loss of expression of certain liver Cyp proteins and liver Cyp-catalyzed testoster-
one hydroxylase activities in global STAT5a-deficient female liver, suggesting a requirement of STAT5a for expression of the corresponding gene products (25). The present qPCR analysis of specific, individual Cyp genes revealed no major effect of global STAT5a deficiency on sex-dependent liver gene expression. Decreases in two Cyp2b RNAs were, however, seen in STAT5a-deficient female livers (Table 2), in agreement with the decrease in Cyp2b protein(s) previously seen in the same mouse model (25), although the present RNA decreases did not reach statistical significance due to individual variation in expression levels.

In summary, the present study provides strong support for the conclusion that the loss of sex-specific liver gene expression in global STAT5b-deficient mice can primarily be ascribed to the loss of STAT5b in hepatocytes. STAT5b is not required for all of the sex-dependent, liver transcriptional regulatory effects of GH, however, as demonstrated by the striking induction of the female-specific Cyp3a16 gene by continuous GH treatment in male mice with hepatocyte-specific STAT5ab deficiency. Hepatocyte STAT5ab-deficient mice did not display the reduced male pubertal growth rate seen earlier in global STAT5b-deficient mice, supporting the conclusion that male GH pulse-stimulated postnatal growth requires STAT5b in one or more extrahepatic tissues. Finally, the lack of major changes in sex-dependent gene expression in global STAT5a-deficient mouse liver indicates that this quantitatively minor liver STAT5 form does not make a global contribution to sex-dependent liver gene expression. Future studies will focus on the molecular mechanisms, both positive and negative, through which hepatocyte STAT5b regulates sexually dimorphic liver gene expression.

Acknowledgments

Received October 23, 2006. Accepted February 8, 2007.

Address all correspondence to: David J. Waxman, Department of Biology, Boston University, 5 Cummington Street, Boston, Massachusetts 02215. E-mail: djw@bu.edu.

This work was supported by National Institutes of Health (NIH) Grant DK33765 (to D.J.W.) and the intramural program of National Institute of Diabetes and Digestive and Kidney Diseases/NIH (to L.H.).

Disclosure Statement: The authors have nothing to disclose.

References


TABLE 2. Sex-specific liver gene expression in global STAT5a-deficient male and female mice

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sex specificity and class</th>
<th>STAT5a+/− male</th>
<th>STAT5a−/− male</th>
<th>STAT5a+/− female</th>
<th>STAT5a−/− female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18S rRNA</td>
<td>MI</td>
<td>1.00 ± 0.04</td>
<td>0.94 ± 0.02</td>
<td>0.95 ± 0.02</td>
<td>1.00 ± 0.06</td>
</tr>
<tr>
<td>Cyp4a12</td>
<td>MI</td>
<td>1.00 ± 0.27</td>
<td>1.20 ± 0.34</td>
<td>0.01± 0.00</td>
<td>0.0&lt;0.01</td>
</tr>
<tr>
<td>Gst π</td>
<td>MI</td>
<td>1.00 ± 0.41</td>
<td>1.10 ± 0.43</td>
<td>0.09 ± 0.06</td>
<td>0.20 ± 0.08</td>
</tr>
<tr>
<td>Slp</td>
<td>MI</td>
<td>1.00 ± 0.21</td>
<td>0.55 ± 0.11</td>
<td>0.02 ± 0.01</td>
<td>0.01 ± 0.00</td>
</tr>
<tr>
<td>Elo13</td>
<td>MI</td>
<td>1.00 ± 0.34</td>
<td>0.56 ± 0.17</td>
<td>&lt;0.01&lt;0.01</td>
<td>0.01 ± 0.00</td>
</tr>
<tr>
<td>Mosd1</td>
<td>MI</td>
<td>1.00 ± 0.66</td>
<td>0.85 ± 0.57</td>
<td>0.01 ± 0.00</td>
<td>0.01 ± 0.00</td>
</tr>
<tr>
<td>Mup3</td>
<td>MI</td>
<td>1.00 ± 0.20</td>
<td>0.83 ± 0.17</td>
<td>0.08 ± 0.03&lt;0.04</td>
<td>0.24 ± 0.04&lt;0.04</td>
</tr>
<tr>
<td>Cyp7b1</td>
<td>MI</td>
<td>1.00 ± 0.23</td>
<td>0.53 ± 0.14</td>
<td>0.07 ± 0.02&lt;0.01</td>
<td>0.08 ± 0.01&lt;0.01</td>
</tr>
<tr>
<td>Hsd3b5</td>
<td>MI</td>
<td>1.00 ± 0.15</td>
<td>1.38 ± 0.37</td>
<td>&lt;0.01&lt;0.01</td>
<td>&lt;0.01&lt;0.01</td>
</tr>
<tr>
<td>S1coa1</td>
<td>MI</td>
<td>1.00 ± 0.25</td>
<td>0.57 ± 0.11</td>
<td>0.10 ± 0.01&lt;0.04</td>
<td>0.16 ± 0.07&lt;0.04</td>
</tr>
<tr>
<td>Cyp2d9</td>
<td>MI</td>
<td>1.00 ± 0.41</td>
<td>1.50 ± 0.37</td>
<td>0.05 ± 0.03&lt;0.01</td>
<td>0.02 ± 0.00&lt;0.01</td>
</tr>
<tr>
<td>Mup1/12/16/8</td>
<td>MI</td>
<td>1.00 ± 0.17</td>
<td>0.97 ± 0.20</td>
<td>0.15 ± 0.06&lt;0.01</td>
<td>0.45 ± 0.38</td>
</tr>
<tr>
<td>Cyp2b9</td>
<td>FI</td>
<td>≤0.01&lt;0.01</td>
<td>≤0.01&lt;0.01</td>
<td>1.00 ± 0.29&lt;0.01</td>
<td>0.37 ± 0.11&lt;0.01</td>
</tr>
<tr>
<td>Cyp2b13</td>
<td>FI</td>
<td>≤0.01&lt;0.01</td>
<td>≤0.01&lt;0.01</td>
<td>1.00 ± 0.29&lt;0.01</td>
<td>0.41 ± 0.12&lt;0.01</td>
</tr>
<tr>
<td>Cyp2a4</td>
<td>FI</td>
<td>0.21 ± 0.07</td>
<td>0.18 ± 0.04</td>
<td>1.00 ± 0.40&lt;0.01</td>
<td>0.57 ± 0.29&lt;0.01</td>
</tr>
<tr>
<td>Cyp39a1</td>
<td>FI</td>
<td>0.31 ± 0.09</td>
<td>0.31 ± 0.27</td>
<td>1.00 ± 0.24&lt;0.01</td>
<td>2.13 ± 0.36</td>
</tr>
<tr>
<td>Nmnt</td>
<td>FI</td>
<td>0.37 ± 0.16</td>
<td>0.38 ± 0.10</td>
<td>1.00 ± 0.42</td>
<td>1.86 ± 0.41&lt;0.01</td>
</tr>
<tr>
<td>Slit1e1</td>
<td>FI</td>
<td>0.02 ± 0.01</td>
<td>0.04 ± 0.02</td>
<td>1.00 ± 0.18&lt;0.01</td>
<td>1.92 ± 1.42</td>
</tr>
<tr>
<td>Cyp3a16</td>
<td>FII</td>
<td>≤0.01&lt;0.01</td>
<td>≤0.01&lt;0.01</td>
<td>1.00 ± 0.19&lt;0.01</td>
<td>0.54 ± 0.13&lt;0.01</td>
</tr>
<tr>
<td>Cyp3a41</td>
<td>FII</td>
<td>≤0.01&lt;0.01</td>
<td>≤0.01&lt;0.01</td>
<td>1.00 ± 0.17&lt;0.01</td>
<td>0.78 ± 0.23&lt;0.01</td>
</tr>
<tr>
<td>Cyp3a44</td>
<td>FII</td>
<td>≤0.01&lt;0.01</td>
<td>≤0.01&lt;0.01</td>
<td>1.00 ± 0.34&lt;0.01</td>
<td>0.78 ± 0.14&lt;0.01</td>
</tr>
</tbody>
</table>

qPCR analysis was carried out using cDNA prepared from total liver RNA isolated from STAT5a wild-type male (n = 6), STAT5a-deficient male (n = 8), STAT5a-wild-type female (n = 4), and STAT5a-deficient female mice (n = 4). Data shown represent relative RNA levels, mean ± se normalized to the 18S rRNA content of each sample and set to 1.0 for wild-type male or female liver, as indicated. Statistical differences were determined by one-way ANOVA with Bonferroni post hoc test and are shown for the following comparisons: STAT5a male vs. STAT5a female (P < 0.05 and P < 0.01). None of the genes displayed a significant difference in expression at P < 0.05 between STAT5a-wild-type and STAT5a-deficient male or female liver. Sex-specificity and class of each gene is represented as male (M) or female (F) and I or II.


Endocrinology is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.